Explore advances in von Willebrand disease treatment, including Star Therapeutics' VGA039, and other key players in the space ...

today announced interim clinical data from VIVID 2 (VGA039 Investigation in Von Willebrand Disease), a Phase 1 single ascending dose (SAD) study of VGA039 in Von Willebrand Disease (VWD ...

The FDA has granted Fast Track Designation to Star Therapeutics’ VGA039, an investigational monoclonal antibody targeting Protein S for the treatment of von Willebrand disease (VWD). According to the ...